Trial now expected to complete enrollment in H2 2018, with data readout expected in H1 2019
90% of patients have continued into a long-term extension study
Rett syndrome is an
Milan, Italy and Morristown, NJ, USA - May 29, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, NJ, USA - May 15, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy – March 27, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy, March 1, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Sponsoring Comprehensive Study to Examine the Burden of Rett Syndrome on Patients and Caregivers; Supporting Standardized Methodology for Health Economic Assessment of Orphan
Milan, Italy – February 8, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Daikichiro Kobayashi, “Meiji”) announced today that
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
